ClinicaliQ Trial Snapshot
- The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction — Recruiting • Cardiology / Cardiovascular • NCT06768437.
- What is being tested: The relationship between epicardial adiposity (fat surrounding the heart) and heart failure with preserved ejection fraction (HFpEF), using advanced imaging (CT and MRI) and biomarker analysis to understand mechanistic pathways in both obese and non-obese patients.
- Patient eligibility overview: The trial recruits 130 patients with confirmed HFpEF across the obesity spectrum (both obese and non-obese individuals), enabling comparative analysis of how adiposity distribution affects this heart failure phenotype.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition. This may lead to the development of new treatments aimed at lowering fat levels around the heart and in the rest of the body, specifically to treat HFpEF.
Eligibility Snapshot
- : * Participant is willing and able to give informed consent for participation in the study. * Aged ≥18 years old * Diagnosed with HFpEF by an experienced cardiologist or signs and symptoms of heart failure with a HFA-PEFF score ≥5 * Able to understand written English
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.